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Abstract
Background: The cervical cancer is the second most prevalent cancer for the woman in the world. It is caused by
the oncogenic human papilloma virus (HPV). The inhibition activity of histone deacetylase (HDAC) is a potential
strategy for cancer therapy. Suberoylanilide hydroxamic acid (SAHA) is widely known as a low toxicity HDAC
inhibitor. This research presents in silico SAHA modification by utilizing triazole, in order to obtain a better inhibitor.
We conducted docking of the SAHA inhibitor and 12 modified versions to six class II HDAC enzymes, and then
proceeded with drug scanning of each one of them.
Results: The docking results show that the 12 modified inhibitors have much better binding affinity and inhibition
potential than SAHA. Based on drug scan analysis, six of the modified inhibitors have robust pharmacological
attributes, as revealed by drug likeness, drug score, oral bioavailability, and toxicity levels.
Conclusions: The binding affinity, free energy and drug scan screening of the best inhibitors have shown that 1c
and 2c modified inhibitors are the best ones to inhibit class II HDAC.
Background
Cervical cancer is one of the most prevalent cancers for
women, and it is the most prevalent one in developing
countries. It is estimated that in the year 2000, there were
470,600 new cervical cancer cases, with 233,400 deaths.
Moreover, 80 % of these cases happened in developing
countries [1]. In Indonesia, it is estimated, that there are
100 new cervical cancer cases per 100,000 people. It is
known that 70% of them are in the late stages [2].
Cervical cancer occurs at the area known as the cervix.
The cause of this cancer is the human papilloma virus
(HPV), a member of the Papillomaviridae family. More
than 120 types of HPV have been identified, and out of
that number, 15 of them are classified as high risk HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73,
and 82) with 12 of them being low risk HPV types (6, 11,
40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). Types 16
and 18 are the main cause of the 70% of cervical cancer
case, while 41-54% caused by Type 16 HPV alone [3].
The most effective and safe method for tackling HPV
infection is still not available, with treatments options
being surgery and/or with physico or chemotherapy [4].
The inhibition of histone deacetylase (HDAC) activity,
which is manifested by the destruction of HDAC complex,
has been widely known as a potent measure to combat
cervical cancer. HDAC (EC 3.5.1) is the enzyme, which
catalyzes the histone deacetylation within eukaryotes. Dea-
cetylation is a release of the acetyl group from the histone
tail, and it causes the histone to be twisted around the
DNA, disrupting gene transcription, by blocking the path-
way of transcription factor binding [5]. The inhibition of
HDAC by its specific inhibitor shows a couple of changes
at the molecular and cellular level [6]. The HDAC activity
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the cancer cell [5].
Vorinostat or suberoylanilide hydroxamic acid (SAHA)
is the most widely used inhibitor of class II HDAC
activity. This inhibitor has carbonyl and hydroxylamine
groups, which will bind to the zinc ion, Zn
2+ ,w i t ht h e
aliphatic chain as linker, and the hydrophobic group in
the other tail. Our research group has successfully deter-
mined the efficacy of SAHA as a potential class II
HDAC inhibitor [4].
We are looking to compare the efficacy of SAHA with
other types of inhibitors, by searching for the new ones
or modifications of the existing ones. Triazole is known
as a non-classical amide bioisostere compound [7]. Tria-
zole could replace the amide bond in the SAHA side
group without losing its activity significantly [8].
We are interested to modify the SAHA compound, by
creating new ones. The processes we have followed are
replacing one of the amides group within the SAHA
hydrophobic group with triazole, and adding triazole as
hydrophobic group toward SAHA. Then, we conduct
molecular docking with Class II HDAC, and testing its
toxicity, and finally compare the result with standard
SAHA inhibitor. This structure-activity relationship
(SAR) study is very important in uncovering novel inhi-
bitors of HDAC.
Material and methods
Collecting the Homo sapiens Class II HDAC sequences and
its 3D structure
Collecting of Homo sapiens Class II HDAC sequences
was done by downloading them from the protein data-
base at NCBI site (http://www.ncbi.nlm.nih.gov). The
Homo sapiens Class II HDAC 3D crystal structure was
downloaded from the PDB structural database site
(http://www.rcsb.org/pdb). The sequences were analyzed
to determine whether there are any newly curated
sequences or not.
Sequence conservation at the Homo sapiens class II HDAC
catalytic site
ClustalW multiple sequence alignment of the collected
Homo sapiens Class II HDAC sequences was carried out.
The alignment results were analyzed with BioEdit, in
order to obtain the existing catalytic site. The conserved
region information was the result of the Homo sapiens
Class II HDAC sequence alignment with its 3D structure
sequences. The sequence for modelling will be the one
that is closely resembles the crystal structure of Homo
sapiens Class II HDAC. This research follows on from
the previous research, which used Class II HDAC Homo
sapiens [4]. If the result of the sequence alignment is the
same with the previous ones, the Class II HDAC Homo
sapiens structure will be generated from it, without the
necessity of conducting another homology modelling
process.
Design of SAHA and modified SAHA inhibitors
This is the beginning of SAR study. The structure of
SAHA and modified SAHA were designed by using
ChemSketch 12.0 software. Various SAHA modifications
were utilized. The output of ChemSketch 12.0 is in the
mol format. It functions as an input for docking simula-
tions with class II HDAC of Homo sapiens, and to test the
pharmacology and toxicity attributes. The ligands were
saved in MDL Molfile format. Then, they were converted
to pdb format by using OpenBabel 2.2.3 or Vegazz
software.
Preparation of class II HDAC Homo sapiens docking
Class II HDAC Homo sapiens structure files were prepared
in pdb format. Then, its variations: HDAC 4, 5, 6, 7, 9, and
10 were loaded with AutoDock Tools, and polar hydrogen
was added to each of those HDAC. The addition is useful
for giving the partial charges/gasteiger charges to those
enzymes. Then, they were saved in pdbqt format. Then,
t h eZ nc h a r g eo fc l a s sI IH D A CHomo sapiens was con-
v e r t e df r o m0t o+ 2b yu s i n gp y t h o ns c r i p t .T h e n ,t h e
molecule was adjusted as macromolecule for the docking
process.
Preparation of class II HDAC Homo sapiens inhibitor file
The inhibitors or ligands in pdb format were loaded with
AutoDock Tools software. Then, the torsion of the ligand
was adjusted based on the total number of rotatable
bonds. Ligands were saved in pdbqt format.
Grid box preparation
The preparation steps were started by using pdb file of
Homo sapiens Class II HDAC as the receptor, and SAHA
with its various ligand modifications. Grid Box is the
coordinate area determination for the docking process. It
is configured in AutoDock Tools. The grid box size for
the docking of HDAC 4, HDAC 5, HDAC 6, HDAC 7,
HDAC 9, and HDAC 10 with the ligands are consecu-
tively 19.228, -6.296, 0.177; 19.696, -6.093, 0.513; 15.326,
-7.608, 8.495; 18.484, -6.198, -0.744; 18.078, -7.314,
-2.129 and 17.713, -6.707, 1.288, with the spacing
between grid points of 0.375 Å. We obtained those num-
bers from our previous research [4]. The best docking
model result was then picked. The grid box was saved in
a grid parameter file (gpf) format.
Docking simulation
This process was done using AutoGrid 4.2 and AutoDock
4.2. The following data are necessary for conducting the
docking: enzyme file in pdbqt format, ligand in pdbqt
format, gpf files, dpf files. The utilized algorithm is
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tion size of 150, energy evaluation of 2.5 x 10
6 and search
runs of 100 times within the RMSD of 1.5.
Analysis and visualization of docking simulation results
The docking result of AutoDock 4.2 is in the docking log
file (dlg) format. Then, by using python script, the dock-
ing results were converted to pdb format. Out of 100-
model result, one best model was picked up, based on
the free energy bonding data, in order to analyze its
interaction.
Drug scan
This was conducted in order to determine, whether the
inhibitor has fulfilled the conditions as the drug candi-
date based on Lipinski’s Rule of Five. It is done using
Lipinski Filters, Molinspiration, Osiris Property Explorer,
Toxtree v2.1.0 and Lazar software.
Molinspiration and Lipinski Filters were utilized for
analyzing the molecular attributes, such as Log P, the
amount of hydrogen bond donors, the amount of hydro-
gen bond acceptor, and the molecular mass of the drugs.
Moreover, the Osiris Property Explorer, Toxtree v2.1.0,
and Lazar calculated various attributes of the drugs, such
as toxicity, drug likeness, and drug score.
In order to use Lipinski Filters, the ligand in pdb format
must be uploaded to the analysis software website. The
same applies to Molinspiration, Lazar, and Toxtree v2.1.0,
because the ligand in smiles format must be uploaded to
their websites. However, to use Osiris Property Explorer,
the ligand could be drawn offline.
Results and discussion
Determination of class II HDAC Homo sapiens
T h er e s u l t so ft h ec l a s sI IH D A CHomo sapiens search
in the NCBI sites are 65 sequences shown in Table 1.
Those sequences were downloaded in FASTA format,
in order to conduct multiple sequences alignment
for each class II HDAC Homo sapiens.T h eo n e sw i t h
the highest score are chosen as the modelling sequences.
The alignment results were compared with the class II
HDAC Homo sapience sequence from previous research
[4]. The obtained sequences for HDAC 4, HDAC 5,
HDAC 6, HDAC 7, HDAC 9, and HDAC 10 are
[Genbank:NP_006028.2, Genbank:NP_005465.2, Gen-
bank:NP_006035.2, Genbank:NP_056216.2, Genbank:
NP_848510.1, and Genbank:NP_114408.3] consecutively.
These sequences are the same as the sequences from
our previous research [4]. Henceforth, this research uti-
lized the 3D structure of class II HDAC Homo sapiens
without the need to redo the homology modelling. Class
II HDAC Homo sapiens has a long chain length (over
than 1000 amino acid). In that case, the modelling was
conducted by extracting the conserved region. The 3D
structure of class II HDAC Homo sapiens are the cataly-
tic area based on its conserved region [4], shown in
Figure 1.
The visualization of the class II HDAC Homo sapiens active
site
The 3D structure of class II HDAC Homo sapiens model-
ling results are saved in pdb format. PyMol visualization
(Figure 2) shows, that the enzyme has cofactor Zn
2+ as
catalytic site, which is bound to three amino acid resi-
dues. These are two aspartic acids and one histidine
residue.
The position of the catalytic sites of each class II
HDAC is different. Table 2 shows the positions of the
catalytic sites of HDAC4, HDAC 5, HDAC 6, HDAC7,
HDAC9, and HDAC 10.
The Design of class II HDAC Homo sapiens inhibitors
12 modified ligands and one standard ligand were drawn
by using ACDLabs ChemSketch 12.0. Those 12 modified
ligands could be classified as two groups. The first one uti-
l i s e st r i a z o l ea ss u b s t i t u e n to ft h ea m i d eg r o u pa tS A H A
(Figure 3). The second one utilises triazole as additional
group of SAHA, without substituting the amide group
(Figure 4). Both modifications are made in their alkyl
groups (R groups) (Figure 5).
T h et r i a z o l eb i o i s o s t e r eattributes on SAHA amide
group could eventually modify SAHA’s properties. The
h y d r o p h o b i ct e n d e n c yo ft r i a z o l ec o m p a r e dw i t ht h e
amide group on SAHA was expected to increase the bind-
ing affinity of modified ligands toward class II HDAC
Homo sapiens. Thus, the binding of enzyme-ligand com-
plex would be much stronger [8]. Triazole could be trea-
ted as an additional functional group on SAHA, which
could increase the hydrophobic attributes of SAHA cap
group [9].
The six alkyl groups for modified ligand variations are
phenyl (C6H5), phenylamine (C6H4NH2), cyclohexyl
(C6H11), fluorophenyl (C6H4F), hydroxyphenyl (C6H4OH),
and iodophenyl (C6H4I). The selections of those alkyl
groups are based on hydrophobic attributes of those
groups. Thus, this study would observe the influence of
the cap group hydrophobicity of each modified ligand, in
comparison with the SAHA standard ligand.
The design of the standard ligand and its modifications
are conducted by clean structure procedure and 3D opti-
mization with ChemSketsch 12.0. The objective of this
treatment is to smooth the designed ligand structure,
while the 3D optimization was conducted to visualize the
ligand when the docking process is running.
Preparation of the enzyme and ligand files for docking
The prepared files for the docking process are enzyme
and ligand in pdbqt format, grid box parameter in gpf
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Page 3 of 15Table 1 Class II HDAC Homo sapiens sequence search result.
Enzyme Sequence
amount
Sequence code
HDAC 4 5 [Genbank: NP_006028.2, Genbank:AAD29046.1, Genbank:EAW71166.1, Genbank:EAW71165.1, Genbank:P56524.3]
HDAC 5 7 [Genbank: AAD29047.1, Genbank: Q9UQL6.2, Genbank: AAH51824.1, Genbank: NP_001015053.1, Genbank: NP_005465.2; EAW51634.1, Genbank: EAW51633.1]
HDAC 6 9 {Genbank:NP_006035.2, Genbank: AAD29048.1, Genbank: AAP35295.1, Genbank: Q9UBN7.2, Genbank: EAW50748.1, Genbank: EAW50747.1, Genbank: EAW50746.1, Genbank:
EAW50745.1, Genbank: EAW50744.1}
HDAC 7 4 [Genbank:AAF63491.1, Genbank: Q8WUI4.2, Genbank: NP_056216.2, Genbank: NP_001091886.1]
HDAC 9 20 [Genbank:AAI52406.1, Genbank: AAI50329.1, Genbank: AAI11736.1, Genbank: NP_848512.1, Genbank: NP_848510.1, Genbank: NP_478056.1, Genbank: NP_055522.1,
Genbank: AAO27363.1, Genbank: AAK66821.1, Genbank: Q9UKV0.2, Genbank: EAW93706.1, Genbank: EAW93705.1, Genbank: EAW93704.1, Genbank: EAW93710.1, Genbank:
EAW93709.1, Genbank: EAW93708.1, Genbank: EAW93707.1, Genbank: EAW93703.1, Genbank: EAW93702.1, Genbank: EAW93701.1]
HDAC
10
20 [Genbank:AAL30513.1, Genbank: AAI25084.1, Genbank: AAS48345.1, Genbank: Q969S8.10, Genbank: NP_001152758.1, Genbank: NP_114408.3, Genbank: AAK92206.1,
Genbank: AAK92205.1, Genbank: AAK84023.1, Genbank: EAW73519.1, Genbank: EAW73518.1, Genbank: EAW73515.1, Genbank: EAW73514.1, Genbank: EAW73513.1,
Genbank: EAW73512.1, Genbank: EAW73511.1, Genbank: EAW73520.1, Genbank: EAW73517.1, Genbank: EAW73516.1, Genbank: BAD92656.1]
T
a
m
b
u
n
a
n
e
t
a
l
.
B
M
C
B
i
o
i
n
f
o
r
m
a
t
i
c
s
2
0
1
1
,
1
2
(
S
u
p
p
l
1
3
)
:
S
2
3
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
1
0
5
/
1
2
/
S
1
3
/
S
2
3
P
a
g
e
4
o
f
1
5format, and docking parameter in dpf format. Pdbqt
Format of enzyme and ligand show that both of them
have undergone partial charge changes and atom type
rearrangement. Zn with zero charge would not be
recognized as a cofactor by the enzyme. Thus, Zn metal
on class II HDAC Homo sapiens must undergo charge




 
Figure 1 Catalytic regions of the crystal structure of HDAC enzymes. A. HDAC 4 Homo sapiens. B. HDAC 5 Homo sapiens. C. HDAC 6 Homo
sapiens. D. HDAC 7 Homo sapiens. E. HDAC 9 Homo sapiens. F. HDAC 10 Homo sapiens. The catalytic regions of the 3D structure of class II HDAC
Homo sapiens shown are based on their conserved regions.
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Page 5 of 15change to Zn
2+ ion. This would be necessary for the
ligand to interact with Zn
2+ cofactor during the docking
process.
When the ligands have been loaded with AutoDock-
Tools, the amount of rotatable bonds were verified. The
rotatable bonds are necessary to arrange the ligand tor-
sional degree for docking process. If the amount of rota-
table bonds and ligand torsional degree are increased,
then the ligands would be more flexible, causing more
variation in the docking process.
The grid box parameters are necessary to describe the
docking process area. The docking parameters are
needed to give necessary conditions in the docking pro-
cess, and include the flexibility of enzyme, the selection
of ligand, and the selection of the utilized algorithm.
Docking
This process is of two types: blind and oriented docking.
Blind docking is a docking process without knowing the
position of the enzyme’s active site, and then during the
grid box determination, the utilized grid center is not
specific to the certain area, but applied to the whole
enzyme area. Oriented docking was done by determine
the position of the enzyme active site, and then the grid
box could be specifically resolved. This research used
oriented docking, because the active site region has
been determined.
Figure 2 The visualization of class II HDAC Homo sapiens active site. PyMol visualization shows, that the utilized enzyme has cofactor Zn
2+
as catalytic site, which is bound to three amino acid (two aspartic acid and one histidine) residues.
Table 2 Location of class II HDAC Homo sapiens catalytic
sites.
Enzyme Location of catalytic site
HDAC 4 Ion Zn
2+ dengan residu Asp193, His195, and Asp287
HDAC 5 Ion Zn
2+ dengan residu Asp178, His180, and Asp272
HDAC 6 Ion Zn
2+ dengan residu Asp71, His73, and Asp164
HDAC 7 Ion Zn
2+ dengan residu Asp191, His193, and Asp285
HDAC 9 Ion Zn
2+ dengan residu Asp188, His190, and Asp282
HDAC 10 Ion Zn
2+ dengan residu Asp133, His135, and Asp226
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Page 6 of 15This docking process is semi-flexible, which means
that the ligand was made flexible, while the enzyme was
rigid. The docking was started by utilize autogrid with
Autogrid 4.2 software. The objective is to map the area
for docking process. The autogrid process was done
using the determined grid box. The dimension of the
utilized grid box must be big enough, in order that the
ligand can be freely rotated [10]. The autogrid result in
grid log file (glg) format would be applied as parameters
for docking process.
This docking process used the Lamarckian Genetic
Algorithm (LGA). This algorithm is recommended,
because it is a hybridization of Local Search and Genetic
Algorithm. The energy evaluation values and utilized
search runs would have impacts on docking duration
and docking energy values. The amounts of search runs
are the total iteration or docking replication [10]. This
study has conducted 100 iterations, and it would result
in 100 inhibitor models on each docking.
Interaction of the inhibitor with class II HDAC Homo
sapiens
The docking results with AutoDock 4.2 were saved in dlg
format. However, visualizing them in 3D graphic requires
conversion to pdb format. The docking results in pdb
can be visualized by PyMol software. One out of 100
models was taken as the best ligand mode, based on the
best binding energy interaction between standard polar
group ligand, and Zn
2+ cofactor modification as enzyme
catalytic site. The chosen interaction is the ligand model
which has Zn
2+ cofactor binding O atom on the C=O
and –OH groups.
The docking result in this study shows, that the stan-
dard SAHA ligand and both modified ligands have equal
amount of interaction toward Zn
2+ cofactor. It is electro-
static attraction of both O atom on C=O and –OH func-
tional groups toward Zn
2+ cofactor. Moreover, the SAHA
standard ligand and both modified ligands have hydrogen
bonds with amino acid residues nearby the Zn
2+ ion.
This case made the binding interaction not applicable for
determining which ligand has the best affinity toward
Zn
2+ . The interaction of SAHA standard ligand and
both modified ligands toward class II HDAC Homo
sapiens are presented in Tables 3 and 4.
Binding free energy (ΔGbinding) and inhibition constant (Ki)
T h er e s u l t so ft h ed o c k i n ga r et h eΔGbinding and Ki
values. The selection of AutoDock 4.2 best model ligand
calculation result was based on the lowest binding free
energy, and ligand interaction toward Zn
2+ ion at the
enzyme. The selection is not based on the cluster result.
The values of the binding free energy and inhibition
Figure 4 The second modification of SAHA ligand. This utilises triazole as additional group of SAHA, without substituting the amide group.
Figure 3 The first modification of SAHA ligand. This utilises triazole as substituent of amide group at SAHA.
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Page 7 of 15constant are available from Tables 5 and 6. The docking
result shows, that all 12 modified ligands have lower
binding free energy and inhibition constant values, com-
pared with the SAHA standard ligand, for every enzyme
in class II HDAC Homo sapiens. Ligand 2c has the
smallest binding free energy and inhibition constant in
HDAC 4 and HDAC 6. Ligand 2f has the smallest values
for HDAC 5. Ligands 2d and 2f have the smallest values
f o rH D A C7 .L a s tb u tn o tl e a s t ,l i g a n d1 ch a st h es m a l -
lest values for HDAC 9 and HDAC 10.
The AutoDock values of ΔGbinding in Table 5 show
that every ligand has negative ΔG. It shows that the
S A H As t a n d a r da n dm o d i f i e dl i g a n dc o n f o r m a t i o n
complex with the tested HDAC, are much more stable
than the individual conformations. It happens because
binding releases energy, which is useful for decreasing
the activation energy of catalytic reaction [4]. The nega-
tive binding free energy shows that the reaction is spon-
taneous. Tables 5 and 6 showed that the binding free
energy values of each ligand are related to its inhibition
constant values. The best ligand for each class II HDAC
Homo sapiens has the smallest ΔGbinding and Ki.
Pharmacology inhibition prediction
Molinspiration, Lipinski Filters, and Osiris Property
Explorer were utilized to screen the drug candidate
Figure 5 The modified alkyl group. Both modifications in figures 3 and 4 are made in their alkyl (R) groups.
Table 3 Interaction of SAHA standard ligand and first modified ligand with class II HDAC Homo sapiens.
Ligand Docking interaction
HDAC 4 HDAC 5 HDAC 6 HDAC 7 HDAC 9 HDAC 10
SAHA Zn
2+, Asp287,
His155, His 195
Zn
2+, Asp272,
His 140
Zn
2+, His32, His33,
Tyr204
Zn
2+, Asp191, His153,
His154
Zn
2+, Asp188, His22,
His150, His151
Zn
2+, Asp226, His95,
His96, Phe163, Tyr266
1a Zn
2+, Asp287,
His155, Pro295
Zn
2+, Asp178,
His140, His180
Zn
2+, His32, His33,
Tyr204
Zn
2+, Asp191, Glu115,
His153
Zn
2+, Asp282, His150,
His151
Zn
2+, Asp133, His95,
His96, Tyr266
1b Zn
2+, Asp193,
His155, Pro295
Zn
2+, Asp178,
His140, His141,
Pro280
Zn
2+, Asp164, His32,
His33, Tyr204
Zn
2+, Ala160, Asp191,
Glu115, His153, His154,
Thr109
Zn
2+, Asp105, Asp107,
Asp188, His150,
His151
Zn
2+, Asn103,
Asp133, His95, His96
1c Zn
2+, Asp193,
His155, Leu296
Zn
2+, Asp178,
His140
Zn
2+, His32, His33,
Thr100, Tyr204
Zn
2+, Asp191, Glu115,
His153, His154, Thr109
Zn
2+, Asp188,
Asp282, His150,
His151
Zn
2+, Asp133, His95,
His96, Tyr226
1d Zn
2+, Asp287,
His155
Zn
2+, Asp178,
His140, Glu102
Zn
2+, His32, Thr100,
Tyr204
Zn
2+, Asp285, Glu115,
His154, Thr109
Zn
2+, Asp188, His150,
His151, Pro290
Zn
2+, Asp133, His95,
His96
1e Zn
2+, Asp193,
His155, Pro295
Zn
2+, Glu102,
Gly149, His140
Zn
2+, Asp164, His32,
His33, Pro103, Tyr204
Zn
2+, Ala160, Asp191,
Glu115, His153, Thr109,
Thr111
Zn
2+, Asp105, His150,
His151
Zn
2+, His95, His96,
Asp133
1f Zn
2+, Asp287,
Gly328, His155,
Pro295
Zn
2+, Asp178,
Gu102, His140
Zn
2+, Asp164, His32,
His33, Thr100, Tyr204
Zn
2+, Asp110, Asp191,
His153, His154, Thr109,
Thr111
Zn
2+, Asp188, His150 Zn
2+, Asp133, His95,
His96
* Bold is the catalytic sites.
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Page 8 of 15based on Lipinski’s Rule of Five and Oral Bioavailability.
The prediction results of the pharmacological attributes
are in Table 7.
The parameters of Lipinski’s Rule of Five are as follows:
the molecular weight must be less than 500 Da, LogP less
than 5, the amount of Hydrogen donor (n OHNH) must
be less than 5, the amount of acceptor hydrogen (n ON)
must be less than 10, and the refractivity molar range
must be between 40-130. The last parameter is optional,
because in the previous research, the emphasized para-
meters are the first four. However, the drug scan result
shows that firstly, the SAHA standard ligand, and sec-
ondly, the modified ligands are in accordance with the
five parameters, with the exception of the molecular
weight of 2f ligand. We could thus infer that the ligands
have successfully passed Lipinski’s Rules.
The oral bioavailability of drugs could be measured by
the molecular weight, number of rotatable bonds (n
rotb), number of hydrogen bonds (n ON and n OHNH),
and the expanse of the drug’s polar surface (TPSA). This
set of criteria is called Veber’s rule. The oral bioavailabil-
ity was marked by small molecular weight (less than
Table 4 Interaction of SAHA standard ligand and second modified ligand with class II HDAC Homo sapiens
Ligand Docking interaction
HDAC 4 HDAC 5 HDAC 6 HDAC 7 HDAC 9 HDAC 10
SAHA Zn
2+, Asp287,
His155, His 195
Zn
2+, Asp272,
His 140
Zn
2+, His32, His33,
Tyr204
Zn
2+, Asp191, His153,
His154
Zn
2+, Asp188, His22,
His150, His151
Zn
2+, Asp226,
His95, His96, Phe163,
Tyr266
2b Zn
2+, Asp193,
Glu117, His155,
Pro162, Tyr167
Zn
2+, His140 Zn
2+, Ala39,
Asp71, His32,
His33, Gly202
Zn
2+, Ala160, Glu115,
His153, Phe163, Thr109,
Thr111
Zn
2+, Asp188, His150,
His151, Pro220
Zn
2+, Asn103,
Asp133, His95,
Phe163
2c Zn
2+, Asp193, His155 Zn
2+, Asp178,
His140
Zn
2+, His32, His33,
Tyr204
Zn
2+, Asp191, Glu115,
His153, Thr109, Thr111
Zn
2+, Asp188, Gly322,
His150, His151
Zn
2+, Asp133,
His95, His96, Phe163
2d Zn
2+, Asp193,
His155, Tyr167
Zn
2+ ,Asp178,
His140, His141,
Glu102
Zn
2+, His32, His33,
Tyr204
Zn
2+, His153, His154,
Phe163
Zn
2+, Asn217, Asp188,
His190
Zn
2+, Asn103,
Asp133, His95,
His96, Tyr266
2e Zn
2+, Asp193, His155 Zn
2+, Asp178,
His140, Tyr60
Zn
2+, Gly99, His32,
His33, Tyr204
Zn
2+, Asp285, Glu115,
Gly326
Zn
2+, Asp188, His150,
His151, His190, Ser19,
Thr20
Zn
2+, Asp133,
Gln98, His96, Phe163
2f Zn
2+, Asp193,
His155, His195
Zn
2+, Asp178,
His140, Phe209
Zn
2+, His32, Thr100 Zn
2+, Asp110, Asp285,
His153, His154
Zn
2+, Asp188, Asp217,
Gly322, His150, His151
Zn
2+, Asn103,
Asp133, His95,
His96,
* Bold is the catalytic sites..
Table 5 The binding free energy docking simulation
result of SAHA standard ligand and its modification
toward class II HDAC Homo sapiens
Ligand Binding energy, ΔG (kcal/mol)
HDAC 4 HDAC 5 HDAC 6 HDAC 7 HDAC 9 HDAC 10
SAHA -7.21 -6.96 -7.19 -7.09 -6.49 -6.95
1a -8.60 -7.90 -7.66 -7.81 -7.84 -9.10
1b -8.08 -7.19 -7.01 -7.88 -7.29 -8.05
1c -7.80 -7.68 -7.54 -8.47 -8.23 -9.43
1d -7.89 -7.55 -7.41 -7.79 -7.51 -8.49
1e -7.47 -7.50 -7.57 -7.63 -7.86 -8.25
1f -9.06 -8.93 -8.10 -9.14 -7.46 -8.43
2a -8.80 -9.60 -8.39 -9.07 -8.05 -8.31
2b -9.38 -9.65 -7.58 -8.74 -7.20 -8.04
2c -9.44 -8.87 -9.75 -9.24 -8.22 -7.94
2d -8.72 -9.22 -8.22 -9.27 -7.88 -8.43
2e -8.69 -9.82 -8.17 -8.67 -6.34 -8.13
2f -9.04 -10.63 -8.50 -9.27 -7.86 -8.20
* Numbers in bold are the lowest amount of binding energy value.
Table 6 Inhibition constant result of standard ligand
docking simulation and modification towards HDAC
Class II
Ligand Inhibition constant, Ki (nM)
HDAC 4 HDAC 5 HDAC 6 HDAC 7 HDAC 9 HDAC 10
SAHA 5160 7940 5350 6400 17600 8100
1a 500 1620 2430 1880 1800 210
1b 1200 5350 7310 1690 4560 1260
1c 1900 2360 7540 610 920 120
1d 1660 2920 63110 1930 3140 590
1e 3360 3150 2820 2560 1740 890
1f 230 290 1150 200 3390 660
2a 360 90 710 220 1250 810
2b 130 80 2760 390 5300 1270
2c 120 310 70 170 940 1500
2d 400 180 940 160 1680 670
2e 430 630 1030 440 22380 1100
2f 240 50 590 160 1730 970
* Numbers in bold are the lowest amount of inhibition constant value.
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Page 9 of 15500); also, the number of rotatable bond must be less
than 10, the number of hydrogen bond donors and
acceptors must be less than 12, and TPSA values less
than 140. Table 7 has shown that the SAHA standard
ligand and the modified ligands have good oral bioava-
ibility, with the exception of 2b, 2d, and 2e ligands.
Those ligands are still in accordance with Veber’s rule.
The hydrophobicity of drugs could be inferred from
Log P value. When its value is increasing, the drug will
be more hydrophobic. When the drug is more hydro-
phobic, then the drug will be able to circulate longer in
our body, because it wouldn’t be easy to secrete it. The
table 7 shows, that the Log P values of the 1c, 1d, 1f, 2a,
2c, 2d, 2e, and 2f modified ligands are larger than the
SAHA standard ligand. It shows that the modified
ligands are more hydrophobic than SAHA. Normally,
drugs, which interact with enzyme inside human body,
have Log P value between 2 and 5 [11]. The table shows
that only modified 1b and 1d ligands, which have log P
value less than 2.
The drug likeness value of standard and modified
ligand shows the fragment content of the drugs. If the
drug likeness values are increasing, than it has the same
fragment content with existing drugs. From Table 7, it
is shown that the drug likeness value of 1a, 1c, 1e, 1f,
2a, 2c, 2d, 2e, and 2f ligands are larger than the SAHA
standard ligand. The highest drug likeness values are in
2f ligand. This result tells us, that the modified ligand
has the most fragments content of drugs.
The drug score values are the combination of drug like-
ness, Log P, solubility, molecular weight, and toxicity risk
within one useful practical value. It could be used for
evaluating the potential of the drug candidate [12]. When
the drug score is better, then the compound has a better
chance to be a drug candidate. Table 7 shows that only
modified 1a and 1e ligands have better drug score than
SAHA standard ligand.
Inhibitor toxicity prediction
This research is using three different softwares to predict
Inhibitor toxicity. They are Osiris Property Explorer,
Toxtree v2.1.0 and Lazar. All of them have different para-
meters for determining the toxicity of compounds. The
prediction using Osiris Property Explorer was shown in
colour codes. The result of toxicity analysis of SAHA
standard ligand, first, and second modified ligands is
shown in table 8.
Green colour shows the low toxicity tendency, yellow
shows the mediocre tendency, and red shows high ten-
dency. Table 8 shows that only 1b and 2b ligands have
high toxicity. This happens because they have mutagenic
aniline group (C6H5NH2). Other ligands have low or
mediocre toxicity.
Table 7 The molecular descriptor value of the SAHA standard ligand and modified ligand
Ligand Molecular weight LogP n ON
1 n OHNH
2 TPSA n rotb Drug likeness Drug score
SAHA 264.325 2.467 5 3 78.42 8 -8.87 0.35
1a 288.351 2.391 6 3 80.04 8 -8.5 0.36
1b 303.366 1.467 7 4 106.07 8 -10.6 0.1
1c 294.399 3.022 6 3 80.04 8 -8.17 0.35
1d 306.341 2.555 6 4 80.04 8 -9.56 0.35
1e 304.35 1.912 7 4 100.27 8 -8.3 0.36
1f 414.247 3.474 6 3 80.04 8 -8.02 0.29
2a 407.474 3.306 8 4 109.14 10 -7.4 0.26
2b 422.489 2.382 9 5 135.17 10 -9.54 0.07
2c 413.522 3.937 8 4 109.14 10 -7.12 0.25
2d 425.464 3.469 8 5 109.14 10 -8.5 0.24
2e 423.473 2.826 9 5 129.37 10 -7.23 0.27
2f 533.37 4.389 8 4 109.14 10 -6.98 0.17
1 = number of hydrogen bonds
2= number of hydrogen bond acceptors
Table 8 Toxicity of SAHA standard and modified ligand
based on Osiris Property Explorer
Ligand Mutagenic Tumorigenic Irritant Reproductive effective
SAHA yellow green green green
1a yellow green green green
1b red red yellow yellow
1c yellow green green green
1d yellow green green green
1e yellow green green green
1f yellow green green green
2a yellow green green green
2b red red yellow yellow
2c yellow green green green
2d yellow green green green
2e yellow green green green
2f yellow green green green
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Page 10 of 15Inhibitor toxicity could be verified by using Toxtree
v2.10, and the result could be seen at table 9.
Toxtree v2.1.0 determined the toxicity level of com-
pounds based on Benigni and Bossa rules. It stipulated
that certain functional groups, which have mutagenic or
carcinogenic properties, could influence the toxicity. The
table 9 shows that 1b and 2b ligands have tendency to be
mutagenic, while 1d, 1f, 2d, and 2f ligands have potential
to be carcinogenic. However, when Toxtree software
result was compared with QSAR analysis, only 2b ligand
has mutagenic potential, and 2d ligand has carcinogenic
potential. SAHA standard ligand and 1a, 1c, 1e, 2a, 2c,
and 2e modified ligands were in accordance of Benigni
and Bossa Rules, because they don’t have potential to be
mutagenic or carcinogenic.
Lazar is a software package with functionality of detect-
ing mutagenic or carcinogenic properties based on the
functional group similarity with mutagenic or carcino-
genic ones. The analysis result of inhibitor toxicity by
lazar could be read at table 10.
Lazar verified the mutagenicity of compounds by con-
ducting assay test with Salmonella typhimurium. Table 10
shows that SAHA standard, first, and second modified
ligands have no mutagenic properties. Moreover, the car-
cinogenicity of compounds was verified by animal testing,
with rodent, Rat, and Mouse. Table 10 also shows that
SAHA standard ligand has no carcinogenic property
toward the three animals. However, the 1e modified ligand
has carcinogenic property toward rodent, 1b and other
second modified ligands were carcinogenic toward mouse.
Screening the best ligand based on docking and drug scan
The best ligands for each class II HDACH Homo sapiens
could be determined based on drug scan and docking
Table 9 Toxicity of SAHA standard and modified ligand based on Toxtree v2.1.0
Ligand Negatif for genotoxic
carcinogenity
Negatif for nongenotoxic
carcinogenity
Potential S.Typhiurium TA 100 mutagen
based on QSAR
Potential carcinogen based
on QSAR
SAHA yes yes no no
1a yes yes no no
1b no yes no no
1c yes yes no no
1d yes no no no
1e yes yes no no
1f yes no no no
2a yes yes no no
2b no yes yes no
2c yes yes no no
2d yes no no yes
2e yes yes no no
2f yes no no no
Table 10 Toxicity analysis result by using Lazar.
Ligand Mutagenicity Carcinogenicity
Salmonella typhimurium(CPDB) Salmonella typhimurium(Kazius/Bursi) Rodent(multiple sex) Rat(both sex) Mouse(both sex)
SAHA no no no no yes
1a no no no no no
1b no no no no yes
1c no no no no no
1d no no no no no
1e no no yes no no
1f no no no no no
2a no no no no yes
2b no no no no yes
2c no no no no yes
2d no no no no yes
2e no no no no yes
2f no no no no yes
Tambunan et al. BMC Bioinformatics 2011, 12(Suppl 13):S23
http://www.biomedcentral.com/1471-2105/12/S13/S23
Page 11 of 15analysis [13]. The best ligand for HDAC4, HDAC6, and
HDAC7 is 2c. It is because the ΔGbinding and Ki of 2c
were the smallest compared with other ligands, with the
exception at HDAC 7. The smallest values of ΔGbinding
a n dK ii nH D A C7w e r eo b t a i n e di n2 da n d2 fl i g a n d .
However, 2d and 2f ligands have bad pharmacological and
 
 
Figure 6 3D Docking simulation results. Interaction between: A. 2c ligand and HDAC 4 Homo sapiens. B. 2a ligand and HDAC 5 Homo sapiens.
C. 2c ligand and HDAC 6 Homo sapiens. D. 2c ligand and HDAC 7 Homo sapiens. E. 1c ligand and HDAC 9 Homo sapiens. F. 1c ligand and HDAC
10 Homo sapiens are shown. The area with yellow circles shows the best ligand interaction with Zn
2+ ion as the enzyme catalytic site.
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Page 12 of 15toxicity attributes, based on drug scan analysis. 2f Ligand
is having a molecular weight, which is beyond the thresh-
old of Lipinski’s Rule parameter. Moreover, the halogen
group on 2d and 2f ligands could cause carcinogenic
property on those ligands. 2c Ligand has good pharmaco-
logical attributes based on drug scan analysis, because it is
in accordance of Lipinski’sR u l e ,V e b e r ’sR u l e ,L o gP
values, toxicity, drug likeness and drug score threshold.
 
 
Figure 7 Surface area of ligand-enzyme interactions. Interactions are shown between A. 2c ligand and HDAC 4 Homo sapiens. B. 2a ligand
and HDAC 5 Homo sapiens. C. 2c ligand and HDAC 6 Homo sapiens. D. 2c ligand and HDAC 7 Homo sapiens. E. 1c ligand and HDAC 9 Homo
sapiens. F. 1c ligand and HDAC 10 Homo sapiens. These show that the cavity of enzyme is deep enough for ligand binding. The depth makes it
necessary to utilize certain ligands with long aliphatic ring, in order for it to enter the cavity, and interact with Zn
2+ ion. Hydrophobic cap group
is necessary as well, in order to guarantee the interaction between ligand’s cap groups with enzyme’s surface area.
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Page 13 of 15The best ligand for HDAC 5 is 2a. This ligand has smal-
ler ΔGbinding and Ki compared with 2f, 2e, and 2b ligands.
However, based on drug scan analysis, 2a ligand has better
pharmacological property. The ligand is in accordance
with Lipinski’s rule parameter and oral bioavailability. 2f,
2e, and 2b ligands were not in accordance to those para-
meters, because of its molecular weight (2f ligand), and
the amount of the hydrogen bond (2b and 2e ligands).
Moreover, the toxicity of 2f and 2b ligands have mutagenic
and carcinogenic tendency, because of the halogen group
(2f ligand) and aniline group (2b ligand). The toxicity of 2a
ligand is lower than 2f and 2b ligands.
The best ligands for HDAC9 and 10 are 1c. It has the
smallest ΔGbinding and Ki compared with the others. 1c
ligand has good pharmacological properties, because it
is in accordance with Lipinski’sR u l e ,V e b e r ’s rule, high
hydrophobicity, and low toxicity.
The property difference among the best ligands on
each class II HDAC Homo sapiens was because of the
characteristic differences among those enzymes. The dif-
ference of catalytic sites of each enzyme causes the inter-
action tendency of ligands to be different as well.
The screening result shows that every ligand has the
same alkyl group, which is cyclohexyl (C6H11). 2a, 1c, 2c
ligands are exceptions. The cyclohexyl group has a high
tendency of hydrophobicity, and it could be seen by its log
P values. This matter would eventually influence the ability
of the group to push the ligand for breaking in the lipid
bilayer, in order for the drug to bind stronger with the
enzyme. Moreover, the hydrophobic group on ligand
would make the interaction between ligand and enzyme
run smoothly [4].
Best ligand 3D visualisation toward class II HDAC Homo
sapiens
Visualisation is the final step of SAR study. The screening
result of the best ligand conformation visualization was
conducted by using PyMOL [14]. The best ligand interac-
tion toward class II HDAC Homo sapiens in 3D could
be seen at figures 6. The area with yellow circles shows the
best ligand interaction with Zn
2+ ion as the enzyme cataly-
t i cs i t e .T h ef i g u r e7s h o w st h es u r f a c ea r e ao fl i g a n d -
enzyme interaction, where it shows that the cavity of
enzyme is deep enough. The depth makes it necessary to
utilize certain ligand with long aliphatic ring, in order for it
to enter the cavity, and interact with Zn
2+ ion [15]. Hydro-
phobic cap group is necessary as well, in order to guarantee
the interaction between ligand’s cap groups with enzyme’s
surface area. Our future step to improve our validation
method is by using Lead-Finder benchmarking tools. [16]
Conclusions
The docking result of SAHA standard, first, and second
modified ligands toward class II HDAC Homo sapiens
shows that those ligands have same type of interaction
toward class II HDAC Homo sapiens, which are utilizing
O atom on C=O group, and its –OH group is binding
to the Zn
2+ ion. The ion is the enzyme’s catalytic site.
Beside, the SAHA standard and modified ligands are
bonded via hydrogen bonds with amino acid residues
around the enzymatic catalytics i t e s .T h e n ,t h ea n a l y s i s
of ΔGbinding and Ki show that every first and second
modified ligands have smaller ΔGbinding and Ki than
SAHA standard ligand. It could be inferred that every
first and second modified ligand has better binding affi-
nity than SAHA standard ligand. The complex of first
and second modified ligand with class II HDAC Homo
sapiens a r em u c hm o r ep r e f e r a b l ec o m p a r e dw i t ht h e
SAHA standard ligand.
Every modified ligand has good pharmacological prop-
erties, and it could be inferred by its accordance with
Lipinskis Rule, Veber’s Rule, hydrophobicity based on log
P value, and good drug likeness and drug score. However,
2b, 2e, and 2f ligands are exceptions. Moreover, only 1a,
1c, 1e, 2a, 2c, and 2e ligands have low toxicity value.
The best ligands according to the binding energy and
drug scan analysis are 1c and 2c ligands, which have the
same alkyl groups, the cyclohexyl (C6H11). In this end,
our SAR study has proven that 1c and 2c inhibitors are
the best inhibitor as alternatives of SAHA.
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